Small Caps - Emyria Launches Empax Global Partnership Platform Targeting International Drug Sponsors
Emyria (ASX:EMD) introduced the Empax global partnership program to enable international drug sponsors to access its established clinical delivery infrastructure.
The world-first service will provide a structured pathway for drug sponsors and clinical research organisations (CROs) to deliver complex treatment protocols through Emyria’s Empax network, supporting clinical trial execution and post-approval commercial rollout.
0
likes
•
0
questions
•
0
company answers
Ask a question
Your question will be sent privately to Emyria. The company may choose to make this question public.
Investor Q&As
Start the conversation
Ask Emyria a question about this update.